Prevalence of Liver Cirrhosis on patients with Chronic Hepatitis C during treatment by Velso 400/100 mg only at The NGaoundere Protestant Hospital in Adamawa Region Cameroon

Introduction: Globally, 71 million people are viremia for HCV infection, about 15 to 25 per cent of infected individuals spontaneously clear the virus, within six months of infection.However, the remaining 75 to 55 per cent will develop chronic HCV. Of those chronically infected, the risk of cirrhosis is 15 to 30 per cent within 20 years with a one to four per cent per annum risk of hepatocellular carcinoma.

Methods: It is descriptive cross –sectional study prevalence of liver cirrhosis done on 35 patients tested positives with HCV confirmed by the following exams such as ELISA HCV, Viral Load HCV among 100 patients presented some clinical manifestations of Chronic Hepatitis C such as jaundice, abdomen pain  hepatosplenomegaly, ascites, hepatic encephalopathy, legs swelling (godet) and abdomen distention at the NGaoundere Protestant Hospital in Adamawa Region Cameroon from June 2023 to September 2023 after receiving Ethical Clearance and Research Authorization from The Health Work of the Evangelical Lutheran Church of Cameroon (HWELCC) Chairman.

Results: The prevalence of chronic hepatitis C on 100 patients was 35% and out to 35 patients tested positive of chronic hepatitis C, the prevalence of Liver Cirrhosis were 82,85%.

Conclusions: This study showed the high level of Liver Cirrhosis prevalence to the patients tested positive with chronic hepatitis C despite taking Velso 400/100 mg(Sofosbuvir 400 mg and velpastavir100mg). To prevent cirrhosis related to hepatitis C, direct oral antiviral therapy (DOAT) is crucial, curing more than 95% of cases. It is essential to eliminate alcohol, adopt a balanced diet, avoid hepatotoxic medications, and get vaccinated against hepatitis A and B